These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25348525)

  • 1. High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.
    Silva-Miranda M; Ekaza E; Breiman A; Asehnoune K; Barros-Aguirre D; Pethe K; Ewann F; Brodin P; Ballell-Pages L; Altare F
    Antimicrob Agents Chemother; 2015 Jan; 59(1):693-7. PubMed ID: 25348525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycobacterium tuberculosis High-Throughput Screening.
    White EL; Tower NA; Rasmussen L
    Methods Mol Biol; 2016; 1439():181-95. PubMed ID: 27316996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-resistant tuberculosis: resistance mechanisms and rapid susceptibility testing.
    Pfyffer GE
    Schweiz Med Wochenschr; 2000 Dec; 130(49):1909-13. PubMed ID: 11153397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?
    Goldman RC
    Tuberculosis (Edinb); 2013 Nov; 93(6):569-88. PubMed ID: 24119636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antimicrobial resistance in tuberculosis].
    Gutiérrez-Aroca JB; Ruiz P; Casal M
    Rev Esp Quimioter; 2013 Dec; 26(4):332-6. PubMed ID: 24399346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
    Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
    Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Approaches to combined therapy of pulmonary tuberculosis in adolescents excreting drug-resistant Mycobacterium tuberculosis].
    Firsova VA; Rusakova LI; Grigor'eva ZP; Ryzhova AP; Iatskova TV; Poluéktova FG
    Probl Tuberk; 2001; (1):28-30. PubMed ID: 11337776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis.
    Gold B; Warrier T; Nathan C
    Methods Mol Biol; 2015; 1285():293-315. PubMed ID: 25779324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activities of antitubercular agents and intensification of combined chemotherapy of tuberculosis].
    Ooizumi K
    Kekkaku; 1983 Sep; 58(9):490-2. PubMed ID: 6420602
    [No Abstract]   [Full Text] [Related]  

  • 10. Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
    Onajole OK; Pieroni M; Tipparaju SK; Lun S; Stec J; Chen G; Gunosewoyo H; Guo H; Ammerman NC; Bishai WR; Kozikowski AP
    J Med Chem; 2013 May; 56(10):4093-103. PubMed ID: 23611124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis.
    Rivas-Santiago B; Rivas Santiago CE; Castañeda-Delgado JE; León-Contreras JC; Hancock RE; Hernandez-Pando R
    Int J Antimicrob Agents; 2013 Feb; 41(2):143-8. PubMed ID: 23141114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An investigation on multiple drug resistance of the rifampin resistant strains of Mycobacterium tuberculosis].
    Kuang T; Jin G; Song P; Li W; Wang Z
    Wei Sheng Wu Xue Bao; 1998 Apr; 38(2):152-4. PubMed ID: 12549378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary drug resistant tuberculosis in Puerto Rico.
    Zack MB; Figueroa-Lebrón RE
    Bol Asoc Med P R; 1974 Nov; 65(11):262-6. PubMed ID: 4217187
    [No Abstract]   [Full Text] [Related]  

  • 14. Antimycobacterial activity of Citrullus colocynthis (L.) Schrad. against drug sensitive and drug resistant Mycobacterium tuberculosis and MOTT clinical isolates.
    Mehta A; Srivastva G; Kachhwaha S; Sharma M; Kothari SL
    J Ethnopharmacol; 2013 Aug; 149(1):195-200. PubMed ID: 23816500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copper-boosting compounds: a novel concept for antimycobacterial drug discovery.
    Speer A; Shrestha TB; Bossmann SH; Basaraba RJ; Harber GJ; Michalek SM; Niederweis M; Kutsch O; Wolschendorf F
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1089-91. PubMed ID: 23254420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistant tuberculosis in Estonia.
    Kruuner A; Sillastu H; Danilovitsh M; Levina K; Svenson SB; Källenius G; Hoffner SE
    Int J Tuberc Lung Dis; 1998 Feb; 2(2):130-3. PubMed ID: 9562123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Editorial: Primary resistance to antitubercular drugs in Puerto Rico].
    Figueras ER
    Bol Asoc Med P R; 1974 Nov; 65(11):280-1. PubMed ID: 4217188
    [No Abstract]   [Full Text] [Related]  

  • 18. [Observations on patients with primary drug resistance of the Mycobacterium tuberculosis].
    Prosvirnov KP; Korol' II; Dobrovol'skaia GI
    Probl Tuberk; 1972; 50(1):82-4. PubMed ID: 4622059
    [No Abstract]   [Full Text] [Related]  

  • 19. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.
    de Steenwinkel JE; de Knegt GJ; ten Kate MT; van Belkum A; Verbrugh HA; Kremer K; van Soolingen D; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2010 Dec; 65(12):2582-9. PubMed ID: 20947621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug resistance of Mycobacterium tuberculosis and its significance in the hospital practice].
    Rudoĭ NM
    Probl Tuberk; 1996; (3):6-8. PubMed ID: 8754863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.